Corcept Therapeutics (CORT) Gains from Investment Securities (2010 - 2026)

Corcept Therapeutics has disclosed Gains from Investment Securities across 16 years of filings, most recently posting $5.8 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $5.8 million, down 63.6% year-over-year; the trailing twelve-month figure through Mar 2026 was -$6.1 million (down 117.8% YoY), and the FY2025 annual result was $13.0 million, down 41.85% from the prior year.
• Gains from Investment Securities came in at $5.8 million for Q1 2026 at Corcept Therapeutics, up from -$23.4 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $39.5 million in Q4 2023 to a low of -$23.4 million in Q4 2025.
• The 5-year median for Gains from Investment Securities is $4.0 million (2025), against an average of $5.7 million.
• Across the five-year window, Gains from Investment Securities jumped 4567.97% in 2023 and sank 435.49% in 2025, its largest moves.
• Corcept Therapeutics' Gains from Investment Securities stood at $846000.0 in 2022, then surged by 4567.97% to $39.5 million in 2023, then plunged by 82.31% to $7.0 million in 2024, then tumbled by 435.49% to -$23.4 million in 2025, then surged by 124.58% to $5.8 million in 2026.
• The last three Gains from Investment Securities figures came in at $5.8 million (Q1 2026), -$23.4 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.